Regeneron Pharmaceuticals Inc Insider Trading
Every director, officer and 10% holder of Regeneron Pharmaceuticals Inc has to report each trade in its stock within two business days of making it. This is those filings.
REGN on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Marion McCourtEVP Commercial2026-09-031.1K shat $857.39 | Sale10b5-1 plan | $969.7K |
| Kathryn GuariniDirector2026-09-02400 shat $850.00 | Sale10b5-1 plan | $340K |
| Marion McCourtEVP Commercial2026-09-021.2K shat $850.00 | Sale10b5-1 plan | $1M |
| Kathryn GuariniDirector2026-08-10400 shat $800.00 | Sale10b5-1 plan | $320K |
| Huda Y ZoghbiDirector2026-08-10800 shat $800.00 | Sale10b5-1 plan | $640K |
| Arthur F RyanDirector2026-07-02200 shat $650.15 | Sale10b5-1 plan | $130K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on REGN
Follow Regeneron Pharmaceuticals Inc (REGN) by email
New trades in Regeneron Pharmaceuticals Inc (REGN) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.